Shares of Novo Nordisk climbed 4.29 during Friday’s pre-market trading session, after rival Eli Lilly’s Phase 3 ATTAIN-1 trial for obesity drug, orforglipron, trailed the Danish drug giant’s semaglutide on Thursday.